https://www.selleckchem.com/products/at-406.html
61, 95% CI 1.33-1.96; high TB HR = 2.03, 95% CI 1.56-2.64). Survival analysis revealed an excellent prognostic discrimination using the TB among the external validation cohort (3-year OS; low TB 44.8%, medium TB 29.3%; high TB 23.3%, p = 0.03; 3-year DFS low TB 32.7%, medium TB 10.7%; high TB 0%, p 0.001). While neoadjuvant chemotherapy was not associated with survival across the TB groups, receipt of adjuvant chemotherapy was associated with increased survival among patients with high TB (5-year OS 24.4% vs 13.4%, p = 0.02). Overal
Curtir
Comentario
Compartilhar
